Evidence map›Paper›PMID 35056970›Full record

ArticlePharmaceutics2021

Efficient Delivery of Hydrophilic Small Molecules to Retinal Cell Lines Using Gel Core-Containing Solid Lipid Nanoparticles.

Li Huang, Erico Himawan, Soumaya Belhadj, Raúl Oswaldo Pérez García, François Paquet Durand, Nicolaas Schipper, Matej Buzgo, Aiva Simaite, Valeria Marigo

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Li HuangDepartment of Life Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy.
Erico HimawanResearch and Development Department, InoCure s.r.o, 11000 Prague, Czech Republic.ORCID 0000-0002-1610-458X
Soumaya BelhadjCell Death Mechanism Group, Institute for Ophthalmic Research, University of Tuebingen, 72076 Tuebingen, Germany.
Raúl Oswaldo Pérez GarcíaDivision Bioeconomy and Health, Chemical Process and Pharmaceutical Development, RISE Research Institutes of Sweden, Forskargatan 18, 151 36 Södertälje, Sweden.
François Paquet DurandCell Death Mechanism Group, Institute for Ophthalmic Research, University of Tuebingen, 72076 Tuebingen, Germany.ORCID 0000-0001-7355-5742
Nicolaas SchipperDivision Bioeconomy and Health, Chemical Process and Pharmaceutical Development, RISE Research Institutes of Sweden, Forskargatan 18, 151 36 Södertälje, Sweden.
Matej BuzgoResearch and Development Department, InoCure s.r.o, 11000 Prague, Czech Republic.
Aiva SimaiteResearch and Development Department, InoCure s.r.o, 11000 Prague, Czech Republic.ORCID 0000-0003-4296-6842
Valeria MarigoDepartment of Life Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy.
RISE Research Institutes of Sweden · SEUniversity of Modena and Reggio Emilia · ITUniversity of Tübingen · DE

Funding

Charlotte and Tistou Kerstan Foundation Charlotte and Tistou Kerstan FoundationEuropean Union H2020-MSCA-ITN-765441
6 · The paper itself

Abstract

In this study, we developed a novel solid lipid nanoparticle (SLN) formulation for drug delivery of small hydrophilic cargos to the retina. The new formulation, based on a gel core and composite shell, allowed up to two-fold increase in the encapsulation efficiency. The type of hydrophobic polyester used in the composite shell mixture affected the particle surface charge, colloidal stability, and cell internalization profile. We validated SLNs as a drug delivery system by performing the encapsulation of a hydrophilic neuroprotective cyclic guanosine monophosphate analog, previously demonstrated to hold retinoprotective properties, and the best formulation resulted in particles with a size of ±250 nm, anionic charge > -20 mV, and an encapsulation efficiency of ±60%, criteria that are suitable for retinal delivery. In vitro studies using the ARPE-19 and 661W retinal cell lines revealed the relatively low toxicity of SLNs, even when a high particle concentration was used. More importantly, SLN could be taken up by the cells and the release of the hydrophilic cargo in the cytoplasm was visually demonstrated. These findings suggest that the newly developed SLN with a gel core and composite polymer/lipid shell holds all the characteristics suitable for the drug delivery of small hydrophilic active molecules into retinal cells.

Indexed as

drug delivery systemretinal pigment epitheliumrod photoreceptorthermoresponsive polymer

Identifiers

PMID35056970
PMCPMC8780956
OpenAlexW4200489850

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.